Prospera Financial Services Inc Sells 8,002 Shares of Vertex Pharmaceuticals Incorporated $VRTX

Prospera Financial Services Inc reduced its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 78.2% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,233 shares of the pharmaceutical company’s stock after selling 8,002 shares during the period. Prospera Financial Services Inc’s holdings in Vertex Pharmaceuticals were worth $875,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Brighton Jones LLC lifted its position in Vertex Pharmaceuticals by 15.0% during the fourth quarter. Brighton Jones LLC now owns 4,427 shares of the pharmaceutical company’s stock valued at $1,783,000 after buying an additional 579 shares during the period. Ritholtz Wealth Management boosted its stake in Vertex Pharmaceuticals by 5.9% during the second quarter. Ritholtz Wealth Management now owns 3,662 shares of the pharmaceutical company’s stock worth $1,630,000 after acquiring an additional 203 shares in the last quarter. Mutual Advisors LLC grew its holdings in Vertex Pharmaceuticals by 6.2% in the second quarter. Mutual Advisors LLC now owns 3,275 shares of the pharmaceutical company’s stock worth $1,538,000 after purchasing an additional 191 shares during the period. Nordea Investment Management AB lifted its holdings in shares of Vertex Pharmaceuticals by 4.5% during the second quarter. Nordea Investment Management AB now owns 24,512 shares of the pharmaceutical company’s stock valued at $10,889,000 after purchasing an additional 1,057 shares during the last quarter. Finally, Angeles Wealth Management LLC boosted its position in shares of Vertex Pharmaceuticals by 2.3% in the 2nd quarter. Angeles Wealth Management LLC now owns 1,284 shares of the pharmaceutical company’s stock worth $572,000 after purchasing an additional 29 shares in the last quarter. 90.96% of the stock is owned by institutional investors.

Vertex Pharmaceuticals Stock Performance

VRTX stock opened at $491.47 on Friday. The company has a market cap of $124.70 billion, a price-to-earnings ratio of 32.06 and a beta of 0.30. The business’s 50-day moving average is $459.98 and its two-hundred day moving average is $427.48. Vertex Pharmaceuticals Incorporated has a fifty-two week low of $362.50 and a fifty-two week high of $519.68.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings results on Thursday, February 12th. The pharmaceutical company reported $5.03 EPS for the quarter, missing the consensus estimate of $5.05 by ($0.02). The business had revenue of $3.19 billion for the quarter, compared to analysts’ expectations of $3.18 billion. Vertex Pharmaceuticals had a net margin of 32.94% and a return on equity of 24.90%. Vertex Pharmaceuticals’s revenue for the quarter was up 9.5% compared to the same quarter last year. During the same period in the previous year, the company earned $3.98 EPS. Equities analysts predict that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current year.

Insiders Place Their Bets

In other Vertex Pharmaceuticals news, EVP Jonathan Biller sold 1,925 shares of the business’s stock in a transaction dated Wednesday, February 11th. The stock was sold at an average price of $460.43, for a total transaction of $886,327.75. Following the completion of the sale, the executive vice president owned 20,819 shares of the company’s stock, valued at approximately $9,585,692.17. The trade was a 8.46% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Charles F. Wagner, Jr. sold 14,000 shares of the company’s stock in a transaction dated Wednesday, December 3rd. The stock was sold at an average price of $456.00, for a total value of $6,384,000.00. Following the completion of the sale, the executive vice president owned 37,725 shares of the company’s stock, valued at approximately $17,202,600. The trade was a 27.07% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 99,352 shares of company stock valued at $45,037,314. 0.20% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

VRTX has been the subject of a number of recent research reports. Wolfe Research raised Vertex Pharmaceuticals from a “peer perform” rating to an “outperform” rating and set a $548.00 target price on the stock in a report on Tuesday, January 6th. Scotiabank upped their target price on shares of Vertex Pharmaceuticals from $495.00 to $558.00 and gave the stock an “outperform” rating in a research note on Friday. Leerink Partners raised their price target on shares of Vertex Pharmaceuticals from $456.00 to $525.00 and gave the company an “outperform” rating in a research report on Monday, December 29th. Weiss Ratings upgraded Vertex Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, February 4th. Finally, UBS Group boosted their price target on Vertex Pharmaceuticals from $535.00 to $545.00 and gave the stock a “buy” rating in a research note on Monday, January 26th. Twenty-two analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $537.05.

More Vertex Pharmaceuticals News

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Revenue and product momentum — Q4 revenue of ~$3.19B (≈+9.5% YoY) came in at or slightly above many forecasts, driven by cystic fibrosis product sales and new launches (Alyftrek, Casgevy, Journavx), supporting near-term cash flow expectations. Article Title
• Positive Sentiment: Analyst upgrade and bullish targets — Oppenheimer upgraded VRTX to “outperform” with a $540 target; several other firms recently raised targets or reiterated buys, which can drive momentum and institutional demand. Article Title
• Positive Sentiment: Pipeline diversification highlighted — Company commentary emphasized growth beyond CF (autoimmune partnerships/expansion), which reduces concentration risk and supports longer-term upside. Article Title
• Neutral Sentiment: 2026 revenue guidance roughly in-line — Management set FY2026 revenue guidance around $13.0–13.1B, largely matching Street expectations; this limits downside from guidance surprises but is not a bullish catalyst on its own. Article Title
• Neutral Sentiment: Full materials available for modeling — The slide deck and earnings call transcript are posted; analysts will parse product trends and margins to update models. Article Title
• Negative Sentiment: Small EPS miss and mixed metric comparisons — EPS was ~$5.03 vs. consensus near $5.05–$5.07; some outlets flagged revenue slightly below certain Street models, triggering near-term profit-taking. Article Title
• Negative Sentiment: Insider selling — Multiple senior executives disclosed open-market sales this week (EVPs, CAO). While common for tax/diversification, the cluster of sales can amplify short-term negative sentiment. Article Title
• Negative Sentiment: After-hours weakness — The EPS miss plus insider sales pressured shares in after-hours trading, reflecting short-term profit-taking before today’s rebound. Article Title

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.